Browsing Tag

Alström

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE®…

Eli Pacheco Feb 24, 2022 0

-- FDA sets updated PDUFA goal date of June 16, 2022 -- -- Company also announces withdrawal of proposed Alström syndrome indication from Type II variation application under review by the…

Health

Rhythm Pharmaceuticals complète la demande de variation de type II à l’Agence…

Eli Pacheco Oct 16, 2021 0

BOSTON, 15 oct. 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq : RYTM), une société biopharmaceutique au stade commercial engagée à transformer les soins des personnes…

Health

Rhythm Pharmaceuticals completa la presentazione della domanda di variazione tipo II…

Eli Pacheco Oct 16, 2021 0

BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), un'azienda biofarmaceutica in fase commerciale impegnata a cambiare radicalmente l'assistenza delle…

Health

Rhythm Pharmaceuticals completa la presentación de la solicitud de variación de tipo…

Eli Pacheco Oct 16, 2021 0

BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), una empresa biofarmacéutica en fase comercial comprometida con la transformación de la atención a…

Health

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the…

Eli Pacheco Oct 15, 2021 0

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living…